Clarfeld Financial Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Clarfeld Financial Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$6K	Buy	+60	New	+$7.09K	0.01%	313

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Clarfeld Financial Advisors's ALXN Position: Q4 2018 in Review

Clarfeld Financial Advisors opened a new position in Alexion Pharmaceuticals (ALXN) in Q4 2018: 60 shares worth $6K. The stake represents 0.01% of the portfolio and ranks #313 among its holdings.

609 funds tracked by Wall St. Rank hold ALXN as of Q4 2018.

Clarfeld Financial Advisors held 60 shares of Alexion Pharmaceuticals worth $6K as of Q4 2018.
Alexion Pharmaceuticals was a new Clarfeld Financial Advisors position in Q4 2018.
Alexion Pharmaceuticals made up 0.01% of Clarfeld Financial Advisors's portfolio in Q4 2018, its #313 holding.
609 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2018.

Based on Clarfeld Financial Advisors's 13F filing for Q4 2018, filed 15 Feb 2019.